BCL2 and B-cell chronic lymphocytic leukemia: Another molecule, UC-961 (Cirmtuzumab) [154,156,157,158], has been studied in patients with chronic lymphocytic leukemia (CLL) as a single agent or in combination with venetoclax (an inhibitor of BCL-2).